Agenda Item 19b

The Queen Elizabeth Hospital King's Lynn
NHS Foundation Trust

REPORT TO THE TRUST BOARD (PUBLIC)

RESPONSIBLE DIRECTOR:	REPORT FOR:		IMPACT ON BUSINESS:		
	Decision		High	Med	Low
Nick Lyons, Medical Director	Discussion	✓		✓	
	Information	✓			
LEAD MANAGER:	**REPORT TYPE:**		**BAF REFERENCES & RAG:**		
Antonia Hardcastle	Strategic				
	Operational				
	Governance	✓	**RELATED WORK: (PREVIOUS PAPERS TO COMMITTEE)**		
PEER ASSIST:	**PEER REVIEW:**				
CQC Domain: (safe, caring, effective, responsive, well-led)	Well-led				

Meeting Date: 27th November 2018

Report Title: Research Update November 2018

PURPOSE:

To update the Board on Research & Development

SUMMARY:

Recruitment into clinical trials is on track, and we have met our targets for the year.
We are opening more commercial clinical trials in different disease specialties
We have had a successful IBD event for patients
We have won a CREST award for breast oncology
2 innovations have been licenced and we are working with Medovate to CE mark the first one as well as design the clinical trials

FINANCIAL IMPLICATIONS / EFFICIENCY SAVINGS / QUALITY IMPROVEMENT:

RISK ASSESSMENT (CROSS-REFERENCE WITH RISK REGISTER WHERE APPROPRIATE):

Strategic / External	Operational/ Organisational	Financial	Clinical	Legal/ Regulatory	Reputational / Patient Experience
✓		✓		✓	✓

RECOMMENDATIONS:

The Board is asked to note the contents of the report

Research Update November 2018

1. **Recruitment**
   We have already exceeded the goals set by the National Institute of Health Research for the year. To date we have recruited 634 patients into clinical trials against the target of 571. We have 35 open and actively recruiting studies, with a further 134 in follow-up. One area of high research activity is Gastroenterology, where we have 7 studies open which follow the course of disease from beginning to end. This has made the department more efficient as patients are screened once for 7 different trials.

2. **Recruitment to time and target**
   The NIHR assess all Trusts in their ability to set up and recruit patients with certain time frames. This is a measure of the efficiency of the research department. The Trust has set up 82% of trials within the 40 day target (4th fastest out of 28 Trusts), and 61% recruited their first participant within 30 days (5th best in the region).

3. **Commercial Studies**
   We currently have 4 open commercial studies, with a further three in the pipeline. These studies are mostly based in renal medicine, but we also recruit to gastroenterology, wound healing and paediatric A&E pain relief. One of our future renal studies will allow clinicians here to undertake the necessary monitoring for the new renal drug for polycystic kidney disease, thus saving the Trust money and enabling our patients to use the drug.

4. **Finance**
   Despite the 6% cut in funding from the Clinical Research Network, we are on track to cover this financial loss. We have achieved the necessary recruitment figures to receive the DHSC's Research Capacity Funding again. We have increased the number of commercial trials to improve our income.

   A new financial model has been agreed by the partnership organisations. This is a mixture of fixed funding, recruitment (both raw and weighted numbers) and delivery to commercial studies. The impact of this on the Trust is unknown at present, but there is a 10% cap and collar which may keep some stability in the department.

5. **Research Dissemination**
   In the past three months we have held our "IBD Research and Me" day, which was featured several times in the local press and on social media.

The idea of the day was to support patients with IBD; to educate them about their disease; to de-mystify research; and to explain what research studies are open. Ali Jawad, a Paralympian power-lifter came and supported us for the day and was an inspiring guest speaker. The local Research network, patient ambassadors and the research team were all there. There was no senior Trust representation on the day.

We have also won the Cancer Research Excellence in Surgical Techniques Award, presented at the National Cancer Research Institute's Annual Conference. The breast oncology team were recognised for great recruitment within a small DGH. Prof. Shaw commended the team: "As a smaller District General Hospital in a rural area, it is impressive to see the high number of patients recruited across a portfolio of many breast cancer trials. These trials include interventional studies such as POSNOC, PRIMETIME and ADD-ASPIRIN and the numbers of patients recruited to the NIHR Portfolio matches or exceeds many larger hospitals. The team also screen patients for other trials, directing them where possible to neighbouring larger trusts in order to improve access for their patients to other complex trials with demanding inclusion criteria. They have shown a significant contribution to the health of their local population, and also to the national collaborative efforts to enhance outcomes for patients with breast cancer"

Endnote – R&D and the Library have joined forces to get the bibliographic software, Endnote, into the Trust. We will run a one year pilot project to look at usage. This software makes referencing for papers/theses/dissertations very easy – which hopefully will improve research output from the trust.

6. **Future plans**
    - We are building collaborations for the future with NCH&C
    - We are aiming to be the Western Research Hub for Norfolk by developing a flexible approach to working across different specialities.
    - We are working closely with Medovate to help CE mark SAFIRA – one of the King's Lynn Innovations. We will then run the clinical trials on the device (estimated start date on Q2 2020)



RECRUITMENT 2018-2019

Recruitment for this year is shown by the black line, against the grey line (17/180 and target (red dotted line)



RECRUITMENT SINCE 2014. This year we are aiming to reach over 1,000.